Ubiquitination and phosphorylation in the regulation of NOD2 signaling and NOD2-mediated disease

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 11, 2012, Pages 2022-2028

  Tigno Aranjuez, Justine T ^a   Abbott, Derek W ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IAP; NOD2; Phosphorylation; RIP2; Ubiquitination

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (2 AMINO 4 PYRIMIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; AEG 35156; AKS 01; AT 406; BIRINAPANT; CASPASE RECRUITMENT DOMAIN PROTEIN 15; ERLOTINIB; GDC 0152; GDC 0917; GEFITINIB; HGS 1029; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; LBW 242; LCL 161; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR BINDING PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ALLERGY; ASTHMA; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BLAU SYNDROME; CROHN DISEASE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ENZYME DEFICIENCY; ENZYME INHIBITION; GAIN OF FUNCTION MUTATION; GENE MUTATION; HAPLOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LOSS OF FUNCTION MUTATION; MULTIPLE SCLEROSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RESPIRATORY TRACT ALLERGY; REVIEW; RHINITIS; SARCOIDOSIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; TH2 CELL; UBIQUITIN PROTEIN LIGASE E3 DEFICIENCY; UBIQUITINATION;

CROHN DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NOD2 SIGNALING ADAPTOR PROTEIN; PHOSPHORYLATION; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84867025024     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.03.017     Document Type: Review

References (85)

1. Lu Z., Hunter T. Degradation of activated protein kinases by ubiquitination. Annu. Rev. Biochem. 2009, 78:435-475.
2. Mukhopadhyay D., Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 2007, 315:201-205.
3. Malynn B.A., Ma A. Ubiquitin makes its mark on immune regulation. Immunity 2010, 33:843-852.
4. Winston J.T., Strack P., Beer-Romero P., Chu C.Y., Elledge S.J., Harper J.W. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev. 1999, 13:270-283.
5. Aragon E., Goerner N., Zaromytidou A.I., Xi Q., Escobedo A., Massague J., Macias M.J. A Smad action turnover switch operated by WW domain readers of a phosphoserine code. Genes Dev. 2011, 25:1275-1288.
6. Inohara N., Ogura Y., Fontalba A., Gutierrez O., Pons F., Crespo J., Fukase K., Inamura S., Kusumoto S., Hashimoto M., Foster S.J., Moran A.P., Fernandez-Luna J.L., Nunez G. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J. Biol. Chem. 2003, 278:5509-5512.
7. Girardin S.E., Boneca I.G., Viala J., Chamaillard M., Labigne A., Thomas G., Philpott D.J., Sansonetti P.J. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 2003, 278:8869-8872.
8. Kobayashi K.S., Chamaillard M., Ogura Y., Henegariu O., Inohara N., Nunez G., Flavell R.A. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005, 307:731-734.
9. Tanabe T., Chamaillard M., Ogura Y., Zhu L., Qiu S., Masumoto J., Ghosh P., Moran A., Predergast M.M., Tromp G., Williams C.J., Inohara N., Nunez G. Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition. EMBO J. 2004, 23:1587-1597.
10. Ogura Y., Inohara N., Benito A., Chen F.F., Yamaoka S., Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J. Biol. Chem. 2001, 276:4812-4818.
11. McCarthy J.V., Ni J., Dixit V.M. RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase. J. Biol. Chem. 1998, 273:16968-16975.
12. Inohara N., Koseki T., Lin J., del Peso L., Lucas P.C., Chen F.F., Ogura Y., Nunez G. An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. J. Biol. Chem. 2000, 275:27823-27831.
13. Pauleau A.L., Murray P.J. Role of nod2 in the response of macrophages to toll-like receptor agonists. Mol. Cell. Biol. 2003, 23:7531-7539.
14. Cooney R., Baker J., Brain O., Danis B., Pichulik T., Allan P., Ferguson D.J., Campbell B.J., Jewell D., Simmons A. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat. Med. 2010, 16:90-97.
15. Travassos L.H., Carneiro L.A., Ramjeet M., Hussey S., Kim Y.G., Magalhaes J.G., Yuan L., Soares F., Chea E., Le Bourhis L., Boneca I.G., Allaoui A., Jones N.L., Nunez G., Girardin S.E., Philpott D.J. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat. Immunol. 2010, 11:55-62.
16. Homer C.R., Richmond A.L., Rebert N.A., Achkar J.P., McDonald C. ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis. Gastroenterology 2010, 139:1630-1641. (1641 e1631-1632).
17. Yang Y., Yin C., Pandey A., Abbott D., Sassetti C., Kelliher M.A. NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J. Biol. Chem. 2007, 282:36223-36229.
18. Abbott D.W., Yang Y., Hutti J.E., Madhavarapu S., Kelliher M.A., Cantley L.C. Coordinated regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains. Mol. Cell. Biol. 2007, 27:6012-6025.
19. Hasegawa M., Fujimoto Y., Lucas P.C., Nakano H., Fukase K., Nunez G., Inohara N. A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. EMBO J. 2008, 27:373-383.
20. Bertrand M.J., Doiron K., Labbe K., Korneluk R.G., Barker P.A., Saleh M. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 2009, 30:789-801.
21. Krieg A., Correa R.G., Garrison J.B., Le Negrate G., Welsh K., Huang Z., Knoefel W.T., Reed J.C. XIAP mediates NOD signaling via interaction with RIP2. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14524-14529.
22. Kanayama A., Seth R.B., Sun L., Ea C.K., Hong M., Shaito A., Chiu Y.H., Deng L., Chen Z.J. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol. Cell 2004, 15:535-548.
23. Wang C., Deng L., Hong M., Akkaraju G.R., Inoue J., Chen Z.J. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001, 412:346-351.
24. Marinis J.M., Homer C.R., McDonald C., Abbott D.W. A novel motif in the Crohn's disease susceptibility protein, NOD2, allows TRAF4 to down-regulate innate immune responses. J. Biol. Chem. 2011, 286:1938-1950.
25. Tao M., Scacheri P.C., Marinis J.M., Harhaj E.W., Matesic L.E., Abbott D.W. ITCH K63-ubiquitinates the NOD2 binding protein, RIP2, to influence inflammatory signaling pathways. Curr. Biol. 2009, 19:1255-1263.
26. Tigno-Aranjuez J.T., Asara J.M., Abbott D.W. Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses. Genes Dev. 2010, 24:2666-2677.
27. Shembade N., Harhaj N.S., Parvatiyar K., Copeland N.G., Jenkins N.A., Matesic L.E., Harhaj E.W. The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nat. Immunol. 2008, 9:254-262.
28. Lee E.G., Boone D.L., Chai S., Libby S.L., Chien M., Lodolce J.P., Ma A. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000, 289:2350-2354.
29. Wertz I.E., O'Rourke K.M., Zhou H., Eby M., Aravind L., Seshagiri S., Wu P., Wiesmann C., Baker R., Boone D.L., Ma A., Koonin E.V., Dixit V.M. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004, 430:694-699.
30. Hitotsumatsu O., Ahmad R.C., Tavares R., Wang M., Philpott D., Turer E.E., Lee B.L., Shiffin N., Advincula R., Malynn B.A., Werts C., Ma A. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 2008, 28:381-390.
31. Hutti J.E., Turk B.E., Asara J.M., Ma A., Cantley L.C., Abbott D.W. IkappaB kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway. Mol. Cell. Biol. 2007, 27:7451-7461.
32. Skaug B., Chen J., Du F., He J., Ma A., Chen Z.J. Direct, noncatalytic mechanism of IKK inhibition by A20. Mol. Cell 2011, 44:559-571.
33. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., Almer S., Tysk C., O'Morain C.A., Gassull M., Binder V., Finkel Y., Cortot A., Modigliani R., Laurent-Puig P., Gower-Rousseau C., Macry J., Colombel J.F., Sahbatou M., Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
34. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., Achkar J.P., Brant S.R., Bayless T.M., Kirschner B.S., Hanauer S.B., Nunez G., Cho J.H. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
35. Hampe J., Cuthbert A., Croucher P.J., Mirza M.M., Mascheretti S., Fisher S., Frenzel H., King K., Hasselmeyer A., MacPherson A.J., Bridger S., van Deventer S., Forbes A., Nikolaus S., Lennard-Jones J.E., Foelsch U.R., Krawczak M., Lewis C., Schreiber S., Mathew C.G. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001, 357:1925-1928.
36. Bonen D.K., Ogura Y., Nicolae D.L., Inohara N., Saab L., Tanabe T., Chen F.F., Foster S.J., Duerr R.H., Brant S.R., Cho J.H., Nunez G. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 2003, 124:140-146.
37. Casanova J.L., Abel L. Revisiting Crohn's disease as a primary immunodeficiency of macrophages. J. Exp. Med. 2009, 206:1839-1843.
38. Noguchi E., Homma Y., Kang X., Netea M.G., Ma X. A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat. Immunol. 2009, 10:471-479.
39. Gutierrez O., Pipaon C., Inohara N., Fontalba A., Ogura Y., Prosper F., Nunez G., Fernandez-Luna J.L. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation. J. Biol. Chem. 2002, 277:41701-41705.
40. Negroni A., Stronati L., Pierdomenico M., Tirindelli D., Di Nardo G., Mancini V., Maiella G., Cucchiara S. Activation of NOD2-mediated intestinal pathway in a pediatric population with Crohn's disease. Inflamm. Bowel Dis. 2009, 15:1145-1154.
41. Stronati L., Negroni A., Merola P., Pannone V., Borrelli O., Cirulli M., Annese V., Cucchiara S. Mucosal NOD2 expression and NF-kappaB activation in pediatric Crohn's disease. Inflamm. Bowel Dis. 2008, 14:295-302.
42. Miceli-Richard C., Lesage S., Rybojad M., Prieur A.M., Manouvrier-Hanu S., Hafner R., Chamaillard M., Zouali H., Thomas G., Hugot J.P. CARD15 mutations in Blau syndrome. Nat. Genet. 2001, 29:19-20.
43. Kanazawa N., Okafuji I., Kambe N., Nishikomori R., Nakata-Hizume M., Nagai S., Fuji A., Yuasa T., Manki A., Sakurai Y., Nakajima M., Kobayashi H., Fujiwara I., Tsutsumi H., Utani A., Nishigori C., Heike T., Nakahata T., Miyachi Y. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 2005, 105:1195-1197.
44. Okafuji I., Nishikomori R., Kanazawa N., Kambe N., Fujisawa A., Yamazaki S., Saito M., Yoshioka T., Kawai T., Sakai H., Tanizaki H., Heike T., Miyachi Y., Nakahata T. Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. Arthritis Rheum. 2009, 60:242-250.
45. Rose C.D., Doyle T.M., McIlvain-Simpson G., Coffman J.E., Rosenbaum J.T., Davey M.P., Martin T.M. Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis. J. Rheumatol. 2005, 32:373-375.
46. Fretzayas A., Moustaki M., Vougiouka O. The puzzling clinical spectrum and course of juvenile sarcoidosis. World J. Pediatr. 2011, 7:103-110.
47. Yanardag H., Pamuk O.N., Uygun S., Demirci S., Karayel T. Sarcoidosis: child vs adult. Indian J. Pediatr. 2006, 73:143-145.
48. Yao Q., Zhou L., Cusumano P., Bose N., Piliang M., Jayakar B., Su L.C., Shen B. A new category of autoinflammatory disease associated with NOD2 gene mutations. Arthritis Res. Ther. 2011, 13:R148.
49. Weidinger S., Klopp N., Rummler L., Wagenpfeil S., Baurecht H.J., Gauger A., Darsow U., Jakob T., Novak N., Schafer T., Heinrich J., Behrendt H., Wichmann H.E., Ring J., Illig T. Association of CARD15 polymorphisms with atopy-related traits in a population-based cohort of Caucasian adults. Clin. Exp. Allergy 2005, 35:866-872.
50. Kabesch M., Peters W., Carr D., Leupold W., Weiland S.K., von Mutius E. Association between polymorphisms in caspase recruitment domain containing protein 15 and allergy in two German populations. J Allergy Clin Immunol 2003, 111:813-817.
51. Daley D., Lemire M., Akhabir L., Chan-Yeung M., He J.Q., McDonald T., Sandford A., Stefanowicz D., Tripp B., Zamar D., Bosse Y., Ferretti V., Montpetit A., Tessier M.C., Becker A., Kozyrskyj A.L., Beilby J., McCaskie P.A., Musk B., Warrington N., James A., Laprise C., Palmer L.J., Pare P.D., Hudson T.J. Analyses of associations with asthma in four asthma population samples from Canada and Australia. Hum. Genet. 2009, 125:445-459.
52. Magalhaes J.G., Fritz J.H., Le Bourhis L., Sellge G., Travassos L.H., Selvanantham T., Girardin S.E., Gommerman J.L., Philpott D.J. Nod2-dependent Th2 polarization of antigen-specific immunity. J. Immunol. 2008, 181:7925-7935.
53. Duan W., Mehta A.K., Magalhaes J.G., Ziegler S.F., Dong C., Philpott D.J., Croft M. Innate signals from Nod2 block respiratory tolerance and program T(H)2-driven allergic inflammation. J. Allergy Clin. Immunol. 2010, 126:1284-1293. (e1210).
54. Magalhaes J.G., Rubino S.J., Travassos L.H., Le Bourhis L., Duan W., Sellge G., Geddes K., Reardon C., Lechmann M., Carneiro L.A., Selvanantham T., Fritz J.H., Taylor B.C., Artis D., Mak T.W., Comeau M.R., Croft M., Girardin S.E., Philpott D.J. Nucleotide oligomerization domain-containing proteins instruct T cell helper type 2 immunity through stromal activation. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:14896-14901.
55. De Jager P.L., Graham R., Farwell L., Sawcer S., Richardson A., Behrens T.W., Compston A., Hafler D.A., Kere J., Vyse T.J., Rioux J.D. The role of inflammatory bowel disease susceptibility loci in multiple sclerosis and systemic lupus erythematosus. Genes Immun. 2006, 7:327-334.
56. Laukens D., Peeters H., Marichal D., Vander Cruyssen B., Mielants H., Elewaut D., Demetter P., Cuvelier C., Van Den Berghe M., Rottiers P., Veys E.M., Remaut E., Steidler L., De Keyser F., De Vos M. CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Ann. Rheum. Dis. 2005, 64:930-935.
57. Peeters H., Vander Cruyssen B., Laukens D., Coucke P., Marichal D., Van Den Berghe M., Cuvelier C., Remaut E., Mielants H., De Keyser F., Vos M.D. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Ann. Rheum. Dis. 2004, 63:1131-1134.
58. Rahman P., Bartlett S., Siannis F., Pellett F.J., Farewell V.T., Peddle L., Schentag C.T., Alderdice C.A., Hamilton S., Khraishi M., Tobin Y., Hefferton D., Gladman D.D. CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am. J. Hum. Genet. 2003, 73:677-681.
59. Giardina E., Novelli G., Costanzo A., Nistico S., Bulli C., Sinibaldi C., Sorgi M.L., Chimenti S., Pallone F., Taccari E., Borgiani P. Psoriatic arthritis and CARD15 gene polymorphisms: no evidence for association in the Italian population. J. Investig. Dermatol. 2004, 122:1106-1107.
60. Lascorz J., Burkhardt H., Huffmeier U., Bohm B., Schurmeyer-Horst F., Lohmann J., Stander M., Wendler J., Kelsch R., Baumann C., Kuster W., Traupe H., Reis A. Lack of genetic association of the three more common polymorphisms of CARD15 with psoriatic arthritis and psoriasis in a German cohort. Ann. Rheum. Dis. 2005, 64:951-954.
61. Jenisch S., Hampe J., Elder J.T., Nair R., Stuart P., Voorhees J.J., Schreiber S., Kabelitz D., Christophers E., Weichenthal M. CARD15 mutations in patients with plaque-type psoriasis and psoriatic arthritis: lack of association. Arch. Dermatol. Res. 2006, 297:409-411.
62. van Beelen A.J., Zelinkova Z., Taanman-Kueter E.W., Muller F.J., Hommes D.W., Zaat S.A., Kapsenberg M.L., de Jong E.C. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 2007, 27:660-669.
63. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annu. Rev. Immunol. 2009, 27:485-517.
64. Shaw P.J., Barr M.J., Lukens J.R., McGargill M.A., Chi H., Mak T.W., Kanneganti T.D. Signaling via the RIP2 adaptor protein in central nervous system-infiltrating dendritic cells promotes inflammation and autoimmunity. Immunity 2011, 34:75-84.
65. Perry W.L., Hustad C.M., Swing D.A., O'Sullivan T.N., Jenkins N.A., Copeland N.G. The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice. Nat. Genet. 1998, 18:143-146.
66. Lohr N.J., Molleston J.P., Strauss K.A., Torres-Martinez W., Sherman E.A., Squires R.H., Rider N.L., Chikwava K.R., Cummings O.W., Morton D.H., Puffenberger E.G. Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease. Am. J. Hum. Genet. 2010, 86:447-453.
67. Thome M., Hofmann K., Burns K., Martinon F., Bodmer J.L., Mattmann C., Tschopp J. Identification of CARDIAK, a RIP-like kinase that associates with caspase-1. Current biology: CB 1998, 8:885-888.
68. Nembrini C., Kisielow J., Shamshiev A.T., Tortola L., Coyle A.J., Kopf M., Marsland B.J. The kinase activity of Rip2 determines its stability and consequently Nod1- and Nod2-mediated immune responses. J. Biol. Chem. 2009, 284:19183-19188.
69. Windheim M., Lang C., Peggie M., Plater L.A., Cohen P. Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide. Biochem. J. 2007, 404:179-190.
70. Inohara N., del Peso L., Koseki T., Chen S., Nunez G. RICK, a novel protein kinase containing a caspase recruitment domain, interacts with CLARP and regulates CD95-mediated apoptosis. J. Biol. Chem. 1998, 273:12296-12300.
71. Dorsch M., Wang A., Cheng H., Lu C., Bielecki A., Charron K., Clauser K., Ren H., Polakiewicz R.D., Parsons T., Li P., Ocain T., Xu Y. Identification of a regulatory autophosphorylation site in the serine-threonine kinase RIP2. Cell. Signal. 2006, 18:2223-2229.
72. Sridhar S.S., Seymour L., Shepherd F.A. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 2003, 4:397-406.
73. Khan P.M., Correa R.G., Divlianska D.B., Peddibhotla S., Sessions E.H., Magnuson G., Brown B., Suyama E., Yuan H., Mangravita-Novo A., Vicchiarelli M., Su Y., Vasile S., Smith L.H., Diaz P.W., Reed J.C., Roth G.P. Identification of Inhibitors of NOD1-Induced Nuclear Factor-kappaB Activation. ACS Med. Chem. Lett. 2011, 2:780-785.
74. Magnuson G., Khan P., Yuan H., Brown B., Divlianska D.B., Stonich D., Peddibhotla M., Su Y., Dad S., Sergienko E., Chung T.D.Y., Roth G.P., Wimer C., Diaz P., Correa R.G., Reed J.C. High Throughput Screening Assays for NOD1 Inhibitors - Probe 2. Probe Reports from the NIH Molecular Libraries Program, Bethesda (MD) 2010.
75. Magnuson G., Khan P., Yuan H., Brown B., Divlianska D.B., Stonich D., Peddibhotla M., Su Y., Dad S., Sergienko E., Chung T.D.Y., Roth G.P., Wimer C., Diaz P., Correa R.G., Reed J.C. High Throughput Screening Assays for NOD1 Inhibitors - Probe 1. Probe Reports from the NIH Molecular Libraries Program, Bethesda (MD) 2010.
76. Bielig H., Velder J., Saiai A., Menning M., Meemboor S., Kalka-Moll W., Kronke M., Schmalz H.G., Kufer T.A. Anti-inflammatory arene chromium complexes acting as specific inhibitors of NOD2 signalling. ChemMedChem 2010, 5:2065-2071.
77. T.A.S., Kufer H.-G., Krnke M., Velder J., Saiar A., Bielig H. Arene chromium-carbonyl complexes, method for their preparation of and use thereof as pharmaceuticals 2010, Germany. U. Cologne (Ed.).
78. Cai Q., Sun H., Peng Y., Lu J., Nikolovska-Coleska Z., McEachern D., Liu L., Qiu S., Yang C.Y., Miller R., Yi H., Zhang T., Sun D., Kang S., Guo M., Leopold L., Yang D., Wang S. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J. Med. Chem. 2011, 54:2714-2726.
79. Last accessed: January 2012. http://www.clinicaltrials.gov.
80. Chauhan D., Neri P., Velankar M., Podar K., Hideshima T., Fulciniti M., Tassone P., Raje N., Mitsiades C., Mitsiades N., Richardson P., Zawel L., Tran M., Munshi N., Anderson K.C. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 2007, 109:1220-1227.
81. McManus D.C., Lefebvre C.A., Cherton-Horvat G., St-Jean M., Kandimalla E.R., Agrawal S., Morris S.J., Durkin J.P., Lacasse E.C. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 2004, 23:8105-8117.
82. Godl K., Wissing J., Kurtenbach A., Habenberger P., Blencke S., Gutbrod H., Salassidis K., Stein-Gerlach M., Missio A., Cotten M., Daub H. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15434-15439.
83. Argast G.M., Fausto N., Campbell J.S. Inhibition of RIP2/RIck/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK. Mol. Cell. Biochem. 2005, 268:129-140.
84. Sabbah A., Chang T.H., Harnack R., Frohlich V., Tominaga K., Dube P.H., Xiang Y., Bose S. Activation of innate immune antiviral responses by Nod2. Nat. Immunol. 2009, 10:1073-1080.
85. Morosky S.A., Zhu J., Mukherjee A., Sarkar S.N., Coyne C.B. Retinoic acid-induced gene-I (RIG-I) associates with nucleotide-binding oligomerization domain-2 (NOD2) to negatively regulate inflammatory signaling. J. Biol. Chem. 2011, 286:28574-28583.